Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)

Authors
Publication date
9 February 2016
Publisher
Georg Thieme Verlag KG
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1055%2Fs-0036-1572...
      Last time updated on 21/04/2021